Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Conference report--protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer; February 24-29, 2004; Lake Tahoe, California.

Literature DB >> 15266251

Conference report--protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer; February 24-29, 2004; Lake Tahoe, California.

Kris Novak.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15266251 PMCID： PMC1395807

Source DB: PubMed Journal: MedGenMed ISSN： 1531-0132

× No keyword cloud information.

14 in total

1. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors: Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245

2. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects.

Authors: Bart S Hendriks; Lee K Opresko; H Steven Wiley; Douglas Lauffenburger
Journal: Cancer Res Date: 2003-03-01 Impact factor: 12.701

Review 3. The emergence of resistance to targeted cancer therapeutics.

Authors: Ingo K Mellinghoff; Charles L Sawyers
Journal: Pharmacogenomics Date: 2002-09 Impact factor: 2.533

Review 4. Inhibiting tyrosine kinases: successes and limitations.

Authors: Carlos L Arteaga
Journal: Cancer Biol Ther Date: 2003 Jul-Aug Impact factor: 4.742

Review 5. Hsp90 as a therapeutic target in prostate cancer.

Authors: David B Solit; Howard I Scher; Neal Rosen
Journal: Semin Oncol Date: 2003-10 Impact factor: 4.929

Review 6. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Authors: Lee F Allen; Judith Sebolt-Leopold; Mark B Meyer
Journal: Semin Oncol Date: 2003-10 Impact factor: 4.929

Review 7. Heat shock protein 90.

Authors: Len Neckers; S Percy Ivy
Journal: Curr Opin Oncol Date: 2003-11 Impact factor: 3.645

8. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962

4. Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway.

Authors: Manuela Malsy; Diane Bitzinger; Bernhard Graf; Anika Bundscherer
Journal: Eur J Med Res Date: 2019-01-28 Impact factor: 2.175

4 in total

Conference report--protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer; February 24-29, 2004; Lake Tahoe, California.

1. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

2. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects.

Review 3. The emergence of resistance to targeted cancer therapeutics.

Review 4. Inhibiting tyrosine kinases: successes and limitations.

Review 5. Hsp90 as a therapeutic target in prostate cancer.

Review 6. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Review 7. Heat shock protein 90.

8. Mutations of the BRAF gene in human cancer.

9. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

Review 10. The clinical applications of heat shock protein inhibitors in cancer - present and future.

Review 1. Kinase inhibitors from marine sponges.

Review 2. Marine Sponges and Bacteria as Challenging Sources of Enzyme Inhibitors for Pharmacological Applications.

3. The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer.

4. Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway.